PharmaCyte Biotech
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell PMCB and other ETFs, options, and stocks.About PMCB
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
CEOJoshua Nathaniel Silverman
CEOJoshua Nathaniel Silverman
Employees2
Employees2
HeadquartersLas Vegas, Nevada
HeadquartersLas Vegas, Nevada
Founded1996
Founded1996
Employees2
Employees2
PMCB Key Statistics
Market cap9.11M
Market cap9.11M
Price-Earnings ratio-0.69
Price-Earnings ratio-0.69
Dividend yield—
Dividend yield—
Average volume324.30K
Average volume324.30K
High today—
High today—
Low today—
Low today—
Open price$0.875
Open price$0.875
Volume0.00
Volume0.00
52 Week high$1.90
52 Week high$1.90
52 Week low$0.63
52 Week low$0.63
Stock Snapshot
With a market cap of 9.11M, PharmaCyte Biotech(PMCB) trades at $0.90. The stock has a price-to-earnings ratio of -0.69.
On 2026-01-23, PharmaCyte Biotech(PMCB) stock opened at $0.88, reached a high of —, and a low of —.
PharmaCyte Biotech(PMCB) shares are trading with a volume of 0, against a daily average of 324.3K.
In the last year, PharmaCyte Biotech(PMCB) shares hit a 52-week high of $1.90 and a 52-week low of $0.63.
In the last year, PharmaCyte Biotech(PMCB) shares hit a 52-week high of $1.90 and a 52-week low of $0.63.
People also own
Based on the portfolios of people who own PMCB. This list is generated using Robinhood data, and it’s not a recommendation.